1	The	_	DT	_	_	2	NMOD	_	_
2	University	_	NNP	_	_	5	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	Toronto	_	NNP	_	_	3	PMOD	_	_
5	stepped	_	VBD	_	_	0	ROOT	_	_
6	deeper	_	RBR	_	_	5	ADV	_	_
7	into	_	IN	_	_	5	DIR	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	contest	_	NN	_	_	7	PMOD	_	_
10	for	_	IN	_	_	9	NMOD	_	_
11	Connaught	_	NNP	_	_	12	NAME	_	_
12	BioSciences	_	NNP	_	_	10	PMOD	_	_
13	Inc.	_	NNP	_	_	12	POSTHON	_	_
14	by	_	IN	_	_	5	MNR	_	_
15	reaching	_	VBG	_	_	14	PMOD	_	_
16	an	_	DT	_	_	18	NMOD	_	_
17	unusual	_	JJ	_	_	18	NMOD	_	_
18	agreement	_	NN	_	_	15	OBJ	_	_
19	with	_	IN	_	_	15	ADV	_	_
20	Ciba-Geigy	_	NNP	_	_	19	PMOD	_	_
21	Ltd.	_	NNP	_	_	20	POSTHON	_	_
22	and	_	CC	_	_	20	COORD	_	_
23	Chiron	_	NNP	_	_	22	CONJ	_	_
24	Corp	_	NNP	_	_	23	POSTHON	_	_
25	.	_	.	_	_	5	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	University	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	6	NMOD	_	_
5	two	_	CD	_	_	6	NMOD	_	_
6	companies	_	NNS	_	_	7	SBJ	_	_
7	agreed	_	VBD	_	_	3	OBJ	_	_
8	to	_	TO	_	_	7	OPRD	_	_
9	spend	_	VB	_	_	8	IM	_	_
10	25	_	CD	_	_	11	DEP	_	_
11	million	_	CD	_	_	13	NMOD	_	_
12	Canadian	_	JJ	_	_	13	NMOD	_	_
13	dollars	_	NNS	_	_	9	OBJ	_	_
14	(	_	(	_	_	13	P	_	_
15	$	_	$	_	_	13	APPO	_	_
16	21.3	_	CD	_	_	15	DEP	_	_
17	million	_	CD	_	_	15	DEP	_	_
18	)	_	)	_	_	13	P	_	_
19	over	_	IN	_	_	9	TMP	_	_
20	10	_	CD	_	_	21	NMOD	_	_
21	years	_	NNS	_	_	19	PMOD	_	_
22	on	_	IN	_	_	9	ADV	_	_
23	research	_	NN	_	_	22	PMOD	_	_
24	at	_	IN	_	_	23	LOC	_	_
25	Canadian	_	JJ	_	_	26	NMOD	_	_
26	universities	_	NNS	_	_	24	PMOD	_	_
27	if	_	IN	_	_	7	ADV	_	_
28	they	_	PRP	_	_	29	SBJ	_	_
29	are	_	VBP	_	_	27	SUB	_	_
30	successful	_	JJ	_	_	29	PRD	_	_
31	in	_	IN	_	_	29	LOC	_	_
32	acquiring	_	VBG	_	_	31	PMOD	_	_
33	the	_	DT	_	_	35	NMOD	_	_
34	vaccine	_	NN	_	_	35	NMOD	_	_
35	maker	_	NN	_	_	32	OBJ	_	_
36	.	_	.	_	_	3	P	_	_

1	It	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	$	_	$	_	_	6	SBJ	_	_
4	10	_	CD	_	_	3	DEP	_	_
5	million	_	CD	_	_	3	DEP	_	_
6	would	_	MD	_	_	2	OBJ	_	_
7	go	_	VB	_	_	6	VC	_	_
8	to	_	TO	_	_	7	DIR	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	University	_	NNP	_	_	8	PMOD	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	Toronto	_	NNP	_	_	11	PMOD	_	_
13	.	_	.	_	_	2	P	_	_

1	Ciba-Geigy	_	NNP	_	_	4	SBJ	_	_
2	and	_	CC	_	_	1	COORD	_	_
3	Chiron	_	NNP	_	_	2	CONJ	_	_
4	have	_	VBP	_	_	0	ROOT	_	_
5	made	_	VBN	_	_	4	VC	_	_
6	a	_	DT	_	_	8	NMOD	_	_
7	joint	_	JJ	_	_	8	NMOD	_	_
8	bid	_	NN	_	_	5	OBJ	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	C$	_	$	_	_	9	PMOD	_	_
11	866	_	CD	_	_	10	DEP	_	_
12	million	_	CD	_	_	10	DEP	_	_
13	for	_	IN	_	_	8	NMOD	_	_
14	Connaught	_	NNP	_	_	13	PMOD	_	_
15	,	_	,	_	_	4	P	_	_
16	and	_	CC	_	_	4	COORD	_	_
17	Institut	_	NNP	_	_	18	NAME	_	_
18	Merieux	_	NNP	_	_	22	SBJ	_	_
19	S.A.	_	NNP	_	_	18	POSTHON	_	_
20	of	_	IN	_	_	18	NMOD	_	_
21	France	_	NNP	_	_	20	PMOD	_	_
22	has	_	VBZ	_	_	16	CONJ	_	_
23	made	_	VBN	_	_	22	VC	_	_
24	a	_	DT	_	_	26	NMOD	_	_
25	rival	_	JJ	_	_	26	NMOD	_	_
26	bid	_	NN	_	_	23	OBJ	_	_
27	of	_	IN	_	_	26	NMOD	_	_
28	C$	_	$	_	_	27	PMOD	_	_
29	942	_	CD	_	_	28	DEP	_	_
30	million	_	CD	_	_	28	DEP	_	_
31	.	_	.	_	_	4	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	University	_	NNP	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	seeking	_	VBG	_	_	3	VC	_	_
5	an	_	DT	_	_	6	NMOD	_	_
6	injunction	_	NN	_	_	4	OBJ	_	_
7	against	_	IN	_	_	6	NMOD	_	_
8	the	_	DT	_	_	10	NMOD	_	_
9	Merieux	_	NNP	_	_	10	NMOD	_	_
10	bid	_	NN	_	_	7	PMOD	_	_
11	,	_	,	_	_	4	P	_	_
12	arguing	_	VBG	_	_	4	ADV	_	_
13	that	_	IN	_	_	12	OBJ	_	_
14	Connaught	_	NNP	_	_	17	NMOD	_	_
15	's	_	POS	_	_	14	SUFFIX	_	_
16	predecessor	_	NN	_	_	17	NMOD	_	_
17	company	_	NN	_	_	18	SBJ	_	_
18	agreed	_	VBD	_	_	13	SUB	_	_
19	in	_	IN	_	_	18	TMP	_	_
20	1972	_	CD	_	_	19	PMOD	_	_
21	that	_	IN	_	_	18	OBJ	_	_
22	Connaught	_	NNP	_	_	24	NMOD	_	_
23	's	_	POS	_	_	22	SUFFIX	_	_
24	ownership	_	NN	_	_	25	SBJ	_	_
25	would	_	MD	_	_	21	SUB	_	_
26	n't	_	RB	_	_	25	ADV	_	_
27	be	_	VB	_	_	25	VC	_	_
28	transferred	_	VBN	_	_	27	VC	_	_
29	to	_	TO	_	_	28	DTV	_	_
30	foreigners	_	NNS	_	_	29	PMOD	_	_
31	.	_	.	_	_	3	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	university	_	NN	_	_	3	SBJ	_	_
3	implied	_	VBD	_	_	0	ROOT	_	_
4	that	_	IN	_	_	3	OBJ	_	_
5	it	_	PRP	_	_	6	SBJ	_	_
6	would	_	MD	_	_	4	SUB	_	_
7	drop	_	VB	_	_	6	VC	_	_
8	its	_	PRP$	_	_	9	NMOD	_	_
9	opposition	_	NN	_	_	7	OBJ	_	_
10	to	_	TO	_	_	9	NMOD	_	_
11	foreign	_	JJ	_	_	12	NMOD	_	_
12	ownership	_	NN	_	_	10	PMOD	_	_
13	if	_	IN	_	_	7	ADV	_	_
14	Ciba-Geigy	_	NNP	_	_	17	SBJ	_	_
15	and	_	CC	_	_	14	COORD	_	_
16	Chiron	_	NNP	_	_	15	CONJ	_	_
17	are	_	VBP	_	_	13	SUB	_	_
18	successful	_	JJ	_	_	17	PRD	_	_
19	with	_	IN	_	_	18	AMOD	_	_
20	their	_	PRP$	_	_	22	NMOD	_	_
21	lower	_	JJR	_	_	22	NMOD	_	_
22	bid	_	NN	_	_	19	PMOD	_	_
23	.	_	.	_	_	3	P	_	_

1	It	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	the	_	DT	_	_	5	NMOD	_	_
4	new	_	JJ	_	_	5	NMOD	_	_
5	agreement	_	NN	_	_	6	SBJ	_	_
6	would	_	MD	_	_	2	OBJ	_	_
7	``	_	``	_	_	8	P	_	_
8	replace	_	VB	_	_	6	VC	_	_
9	''	_	''	_	_	8	P	_	_
10	the	_	DT	_	_	12	NMOD	_	_
11	old	_	JJ	_	_	12	NMOD	_	_
12	one	_	CD	_	_	8	OBJ	_	_
13	that	_	WDT	_	_	14	SBJ	_	_
14	forms	_	VBZ	_	_	12	NMOD	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	basis	_	NN	_	_	14	OBJ	_	_
17	of	_	IN	_	_	16	NMOD	_	_
18	its	_	PRP$	_	_	19	NMOD	_	_
19	suit	_	NN	_	_	17	PMOD	_	_
20	against	_	IN	_	_	19	NMOD	_	_
21	the	_	DT	_	_	23	NMOD	_	_
22	Merieux	_	NNP	_	_	23	NMOD	_	_
23	takeover	_	NN	_	_	20	PMOD	_	_
24	.	_	.	_	_	2	P	_	_

1	``	_	``	_	_	19	P	_	_
2	Notwithstanding	_	IN	_	_	10	ADV	_	_
3	foreign	_	JJ	_	_	4	NMOD	_	_
4	ownership	_	NN	_	_	2	PMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	Connaught	_	NNP	_	_	5	PMOD	_	_
7	,	_	,	_	_	10	P	_	_
8	this	_	DT	_	_	9	NMOD	_	_
9	accord	_	NN	_	_	10	SBJ	_	_
10	would	_	MD	_	_	19	OBJ	_	_
11	enhance	_	VB	_	_	10	VC	_	_
12	research	_	NN	_	_	11	OBJ	_	_
13	and	_	CC	_	_	12	COORD	_	_
14	development	_	NN	_	_	13	CONJ	_	_
15	in	_	IN	_	_	12	LOC	_	_
16	Canada	_	NNP	_	_	15	PMOD	_	_
17	,	_	,	_	_	19	P	_	_
18	''	_	''	_	_	19	P	_	_
19	said	_	VBD	_	_	0	ROOT	_	_
20	James	_	NNP	_	_	21	NAME	_	_
21	Keffer	_	NNP	_	_	19	SBJ	_	_
22	,	_	,	_	_	21	P	_	_
23	the	_	DT	_	_	24	NMOD	_	_
24	university	_	NN	_	_	27	NMOD	_	_
25	's	_	POS	_	_	24	SUFFIX	_	_
26	vice	_	NN	_	_	27	NMOD	_	_
27	president	_	NN	_	_	21	APPO	_	_
28	of	_	IN	_	_	27	NMOD	_	_
29	research	_	NN	_	_	28	PMOD	_	_
30	.	_	.	_	_	19	P	_	_

1	Ciba-Geigy	_	NNP	_	_	2	SBJ	_	_
2	is	_	VBZ	_	_	0	ROOT	_	_
3	a	_	DT	_	_	6	NMOD	_	_
4	Swiss	_	JJ	_	_	6	NMOD	_	_
5	pharmaceutical	_	JJ	_	_	6	NMOD	_	_
6	company	_	NN	_	_	2	PRD	_	_
7	and	_	CC	_	_	2	COORD	_	_
8	Chiron	_	NNP	_	_	9	SBJ	_	_
9	is	_	VBZ	_	_	7	CONJ	_	_
10	based	_	VBN	_	_	9	VC	_	_
11	in	_	IN	_	_	10	LOC	_	_
12	Emeryville	_	NNP	_	_	11	PMOD	_	_
13	,	_	,	_	_	12	P	_	_
14	Calif	_	NNP	_	_	12	APPO	_	_
15	.	_	.	_	_	2	P	_	_

1	In	_	IN	_	_	13	LOC	_	_
2	a	_	DT	_	_	3	NMOD	_	_
3	statement	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	13	P	_	_
5	Jacques-Francois	_	NNP	_	_	6	NAME	_	_
6	Martin	_	NNP	_	_	13	SBJ	_	_
7	,	_	,	_	_	6	P	_	_
8	director	_	NN	_	_	9	NMOD	_	_
9	general	_	NN	_	_	6	APPO	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	Merieux	_	NNP	_	_	10	PMOD	_	_
12	,	_	,	_	_	6	P	_	_
13	said	_	VBD	_	_	0	ROOT	_	_
14	the	_	DT	_	_	16	NMOD	_	_
15	French	_	JJ	_	_	16	NMOD	_	_
16	company	_	NN	_	_	17	SBJ	_	_
17	is	_	VBZ	_	_	13	OBJ	_	_
18	still	_	RB	_	_	17	ADV	_	_
19	determined	_	VBN	_	_	17	PRD	_	_
20	to	_	TO	_	_	19	AMOD	_	_
21	acquire	_	VB	_	_	20	IM	_	_
22	Connaught	_	NNP	_	_	21	OBJ	_	_
23	.	_	.	_	_	13	P	_	_

1	While	_	IN	_	_	17	ADV	_	_
2	he	_	PRP	_	_	3	SBJ	_	_
3	did	_	VBD	_	_	1	SUB	_	_
4	n't	_	RB	_	_	3	ADV	_	_
5	comment	_	NN	_	_	3	VC	_	_
6	directly	_	RB	_	_	5	MNR	_	_
7	on	_	IN	_	_	5	ADV	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	pact	_	NN	_	_	7	PMOD	_	_
10	between	_	IN	_	_	9	NMOD	_	_
11	Ciba-Geigy	_	NNP	_	_	10	PMOD	_	_
12	and	_	CC	_	_	11	COORD	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	university	_	NN	_	_	12	CONJ	_	_
15	,	_	,	_	_	17	P	_	_
16	he	_	PRP	_	_	17	SBJ	_	_
17	said	_	VBD	_	_	0	ROOT	_	_
18	Merieux	_	NNP	_	_	19	SBJ	_	_
19	can	_	MD	_	_	17	OBJ	_	_
20	transfer	_	VB	_	_	19	VC	_	_
21	new	_	JJ	_	_	22	NMOD	_	_
22	products	_	NNS	_	_	20	OBJ	_	_
23	and	_	CC	_	_	22	COORD	_	_
24	technologies	_	NNS	_	_	23	CONJ	_	_
25	to	_	TO	_	_	20	ADV	_	_
26	Connaught	_	NNP	_	_	25	PMOD	_	_
27	more	_	RBR	_	_	28	AMOD	_	_
28	rapidly	_	RB	_	_	20	MNR	_	_
29	than	_	IN	_	_	28	AMOD	_	_
30	other	_	JJ	_	_	31	NMOD	_	_
31	companies	_	NNS	_	_	29	PMOD	_	_
32	``	_	``	_	_	31	P	_	_
33	not	_	RB	_	_	35	ADV	_	_
34	currently	_	RB	_	_	35	TMP	_	_
35	producing	_	VBG	_	_	31	APPO	_	_
36	and	_	CC	_	_	35	COORD	_	_
37	marketing	_	VBG	_	_	36	CONJ	_	_
38	vaccines	_	NNS	_	_	35	OBJ	_	_
39	{	_	(	_	_	42	P	_	_
40	who	_	WP	_	_	42	SBJ	_	_
41	}	_	)	_	_	42	P	_	_
42	can	_	MD	_	_	31	NMOD	_	_
43	only	_	RB	_	_	42	ADV	_	_
44	promise	_	VB	_	_	42	VC	_	_
45	this	_	DT	_	_	44	OBJ	_	_
46	for	_	IN	_	_	44	ADV	_	_
47	some	_	DT	_	_	49	NMOD	_	_
48	...	_	:	_	_	49	P	_	_
49	years	_	NNS	_	_	46	PMOD	_	_
50	in	_	IN	_	_	49	TMP	_	_
51	the	_	DT	_	_	52	NMOD	_	_
52	future	_	NN	_	_	50	PMOD	_	_
53	.	_	.	_	_	17	P	_	_
54	''	_	''	_	_	17	P	_	_

1	In	_	IN	_	_	8	LOC	_	_
2	national	_	JJ	_	_	4	NMOD	_	_
3	over-the-counter	_	JJ	_	_	4	NMOD	_	_
4	trading	_	NN	_	_	1	PMOD	_	_
5	yesterday	_	NN	_	_	8	TMP	_	_
6	,	_	,	_	_	8	P	_	_
7	Connaught	_	NNP	_	_	8	SBJ	_	_
8	closed	_	VBD	_	_	0	ROOT	_	_
9	at	_	IN	_	_	8	ADV	_	_
10	$	_	$	_	_	9	PMOD	_	_
11	28.625	_	CD	_	_	10	NMOD	_	_
12	,	_	,	_	_	8	P	_	_
13	up	_	IN	_	_	8	ADV	_	_
14	$	_	$	_	_	13	AMOD	_	_
15	1.25	_	CD	_	_	14	NMOD	_	_
16	.	_	.	_	_	8	P	_	_

